Takeda Pharmaceutical Co. Ltd. has bolstered its growing immuno-oncology arsenal with the acquisition of Maverick Therapeutics, Inc., a private company developing bispecific antibodies, adding another area of high-value cancer immunotherapy to its pipeline of cell therapies.
The Osaka, Japan-based drug maker said 9 March that it would exercise an option to acquire the Brisbane, CA-based Maverick for up to $525m, under a “build-to-buy” deal that the two